These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Vismodegib resistance in basal cell carcinoma: not a smooth fit. Ridky TW; Cotsarelis G Cancer Cell; 2015 Mar; 27(3):315-6. PubMed ID: 25759014 [TBL] [Abstract][Full Text] [Related]
3. Acquired resistance to the Hedgehog pathway inhibitor vismodegib due to smoothened mutations in treatment of locally advanced basal cell carcinoma. Brinkhuizen T; Reinders MG; van Geel M; Hendriksen AJ; Paulussen AD; Winnepenninckx VJ; Keymeulen KB; Soetekouw PM; van Steensel MA; Mosterd K J Am Acad Dermatol; 2014 Nov; 71(5):1005-8. PubMed ID: 25199678 [No Abstract] [Full Text] [Related]
4. Smoothened variants explain the majority of drug resistance in basal cell carcinoma. Atwood SX; Sarin KY; Whitson RJ; Li JR; Kim G; Rezaee M; Ally MS; Kim J; Yao C; Chang AL; Oro AE; Tang JY Cancer Cell; 2015 Mar; 27(3):342-53. PubMed ID: 25759020 [TBL] [Abstract][Full Text] [Related]
5. Vismodegib resistant mutations are not selected in multifocal relapses of locally advanced basal cell carcinoma after vismodegib discontinuation. Ighilahriz M; Benfodda M; Sharpe H; Soufir N; Mourah S; Dumaz N; Battistella M; Savina A; Bouquet F; Nikolaev S; Basset-Seguin N J Eur Acad Dermatol Venereol; 2019 Nov; 33(11):e422-e424. PubMed ID: 31187903 [No Abstract] [Full Text] [Related]